Literature DB >> 25122565

In vitro assay of six UDP-glucuronosyltransferase isoforms in human liver microsomes, using cocktails of probe substrates and liquid chromatography-tandem mass spectrometry.

Kyung-Ah Seo1, Hyo-Ji Kim1, Eun Sook Jeong1, Nagi Abdalla1, Chang-Soo Choi1, Dong-Hyun Kim2, Jae-Gook Shin2.   

Abstract

UDP-glucuronosyltransferase (UGT)-mediated drug-drug interactions are commonly evaluated during drug development. We present a validated method for the simultaneous evaluation of drug-mediated inhibition of six major UGT isoforms, developed in human liver microsomes through the use of pooled specific UGT probe substrates (cocktail assay) and rapid liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. The six probe substrates used in this assay were estradiol (UGT1A1), chenodeoxycholic acid (UGT1A3), trifluoperazine (UGT1A4), 4-hydroxyindole (UGT1A6), propofol (UGT1A9), and naloxone (UGT2B7). In a cocktail incubation, UGT1A1, UGT1A9, and UGT2B7 activities were substantially inhibited by other substrates. This interference could be eliminated by dividing substrates into two incubations: one containing estradiol, trifluoperazine, and 4-hydroxyindole, and the other containing chenodeoxycholic acid, propofol, and naloxone. Incubation mixtures were pooled for the simultaneous analysis of glucuronyl conjugates in a single LC-MS/MS run. The optimized cocktail method was further validated against single-probe substrate assays using compounds known to inhibit UGTs. The degree of inhibition of UGT isoform activities by such known inhibitors in this cocktail assay was not substantially different from that in single-probe assays. This six-isoform cocktail assay may be very useful in assessing the UGT-based drug-interaction potential of candidates in a drug-discovery setting.
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25122565     DOI: 10.1124/dmd.114.058818

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  8 in total

1.  Toxicity, pharmacokinetics and metabolism of a novel inhibitor of IL-6-induced STAT3 activation.

Authors:  Brian F Kiesel; Robert A Parise; Jianxia Guo; Donna M Huryn; Paul A Johnston; Raffaele Colombo; Malabika Sen; Jennifer R Grandis; Jan H Beumer; Julie L Eiseman
Journal:  Cancer Chemother Pharmacol       Date:  2016-10-24       Impact factor: 3.333

2.  LC-MS/MS assay for the quantitation of the ATR kinase inhibitor VX-970 in human plasma.

Authors:  Brian F Kiesel; Jonas Scemama; Robert A Parise; Liza Villaruz; Andre Iffland; Austin Doyle; Percy Ivy; Edward Chu; Christopher J Bakkenist; Jan H Beumer
Journal:  J Pharm Biomed Anal       Date:  2017-08-31       Impact factor: 3.935

Review 3.  The Ontogeny of UDP-glucuronosyltransferase Enzymes, Recommendations for Future Profiling Studies and Application Through Physiologically Based Pharmacokinetic Modelling.

Authors:  Justine Badée; Stephen Fowler; Saskia N de Wildt; Abby C Collier; Stephan Schmidt; Neil Parrott
Journal:  Clin Pharmacokinet       Date:  2019-02       Impact factor: 6.447

4.  Age- and Genotype-Dependent Variability in the Protein Abundance and Activity of Six Major Uridine Diphosphate-Glucuronosyltransferases in Human Liver.

Authors:  Deepak Kumar Bhatt; Aanchal Mehrotra; Andrea Gaedigk; Revathi Chapa; Abdul Basit; Haeyoung Zhang; Prachi Choudhari; Mikael Boberg; Robin E Pearce; Roger Gaedigk; Ulrich Broeckel; J Steven Leeder; Bhagwat Prasad
Journal:  Clin Pharmacol Ther       Date:  2018-07-12       Impact factor: 6.875

5.  Identifying and applying a highly selective probe to simultaneously determine the O-glucuronidation activity of human UGT1A3 and UGT1A4.

Authors:  Li Jiang; Si-Cheng Liang; Chao Wang; Guang-Bo Ge; Xiao-Kui Huo; Xiao-Yi Qi; Sa Deng; Ke-Xin Liu; Xiao-Chi Ma
Journal:  Sci Rep       Date:  2015-04-17       Impact factor: 4.379

6.  Regioselective Glucuronidation of Diosmetin and Chrysoeriol by the Interplay of Glucuronidation and Transport in UGT1A9-Overexpressing HeLa Cells.

Authors:  Xuejun Zeng; Jian Shi; Min Zhao; Qingwei Chen; Liping Wang; Huangyu Jiang; Feifei Luo; Lijun Zhu; Linlin Lu; Xinchun Wang; Zhongqiu Liu
Journal:  PLoS One       Date:  2016-11-10       Impact factor: 3.240

Review 7.  Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development.

Authors:  Yurong Lai; Xiaoyan Chu; Li Di; Wei Gao; Yingying Guo; Xingrong Liu; Chuang Lu; Jialin Mao; Hong Shen; Huaping Tang; Cindy Q Xia; Lei Zhang; Xinxin Ding
Journal:  Acta Pharm Sin B       Date:  2022-03-17       Impact factor: 14.903

8.  Human variability in isoform-specific UDP-glucuronosyltransferases: markers of acute and chronic exposure, polymorphisms and uncertainty factors.

Authors:  E E J Kasteel; K Darney; N I Kramer; J L C M Dorne; L S Lautz
Journal:  Arch Toxicol       Date:  2020-05-15       Impact factor: 5.153

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.